Skip to content
Discover expert articles on marketing strategies, promotion…

Users Coming Off Slimming Medications Put On Weight Four Times Faster Than Those on Conventional Diets

Illustration of pharmaceutical injection and scale
Obesity treatment often requires ongoing approaches.

A recent study indicates that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass far faster than those who end traditional lifestyle regimens.

Findings released in a leading health publication demonstrates that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.

"People using such drugs must be aware of the potential of fast rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.

This pace of recovery suggests a reversion to starting weight in about 18 months.

Weighing Approaches

The research, which examined 37 of trials involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.

Researchers point out that individuals who shed pounds through lifestyle changes alone generally experience a less rapid creep back—around 100 grams monthly—post-intervention.

Explaining the Rapid Rebound

Nutrition scientists propose the mode of action of the drugs is key to understanding the heightened regain.

These medications imitate a body's own chemical called GLP-1, which helps regulate hunger.

"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the body to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.

"Stopping of this medication results in hunger is uncontrolled, making overeating a significant risk."

A Chronic Condition?

The NHS suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.

Professionals argue that, due to the significant potential of relapse, the therapy might need to be ongoing.

This perspective is echoed by pharmaceutical companies, who say that the results "highlight the chronic character of obesity," akin to managing diseases like diabetes.

Patient Testimonies

Individuals who have come off the medication report a sudden return of appetite.

"It was like a switch flipping and I was suddenly extremely hungry," described a patient.

The struggle is exacerbated if patients have not developed lasting lifestyle or habit changes during therapy.

Significant Interest

Figures show that millions of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.

  • Adoption is greater among women compared to men.
  • The 40s and 50s demographic shows the highest usage rates.
  • A large proportion access the drugs through private prescriptions rather than public health services.

Finally, clinicians emphasize that while the jabs are effective tools for shedding pounds, they are not a standalone fix and maintained weight loss relies on integrated behavioural changes.

TM
By

Tara Mahoney

Senior marketing strategist with 8+ years experience in digital promotion and brand growth.

PromoInsight UK

Type to search articles.